Cargando…

Leukaemias and cancers following iodine-131 administration for thyroid cancer.

We studied 1771 patients treated for a thyroid cancer in two institutions. None of these patients had been treated with external radiotherapy and 1497 had received (131)I. The average (131)I cumulative activity administered was 7.2 GBq, and the estimated average dose was 0.34 Sv to the bone marrow a...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vathaire, F., Schlumberger, M., Delisle, M. J., Francese, C., Challeton, C., de la Genardiére, E., Meunier, F., Parmentier, C., Hill, C., Sancho-Garnier, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063327/
https://www.ncbi.nlm.nih.gov/pubmed/9043033
_version_ 1782137313760903168
author de Vathaire, F.
Schlumberger, M.
Delisle, M. J.
Francese, C.
Challeton, C.
de la Genardiére, E.
Meunier, F.
Parmentier, C.
Hill, C.
Sancho-Garnier, H.
author_facet de Vathaire, F.
Schlumberger, M.
Delisle, M. J.
Francese, C.
Challeton, C.
de la Genardiére, E.
Meunier, F.
Parmentier, C.
Hill, C.
Sancho-Garnier, H.
author_sort de Vathaire, F.
collection PubMed
description We studied 1771 patients treated for a thyroid cancer in two institutions. None of these patients had been treated with external radiotherapy and 1497 had received (131)I. The average (131)I cumulative activity administered was 7.2 GBq, and the estimated average dose was 0.34 Sv to the bone marrow and 0.80 Sv to the whole body. After a mean follow-up of 10 years, no case of leukaemia was observed, compared with 2.5 expected according to the coefficients derived from Japanese atomic bomb survivors (P = 0.1). A total of 80 patients developed a solid second malignant neoplasm (SMN), among whom 13 developed a colorectal cancer. The risk of colorectal cancer was found to be related to the total activity of (131)I administered 5 years or more before its diagnosis (excess relative risk = 0.5 per GBq, P = 0.02). These findings were probably caused by the accumulation of (131)I in the colon lumen. Hence, in the absence of laxative treatment, the dose to the colon as a result of (131)I administered for the treatment of thyroid cancer could be higher than expected from calculation of the International Commission on Radiological Protection (ICRP). When digestive tract cancers were excluded, the overall excess relative risk of second cancer per estimated effective sievert received to the whole body was -0.2 (P = 0.6). IMAGES:
format Text
id pubmed-2063327
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20633272009-09-10 Leukaemias and cancers following iodine-131 administration for thyroid cancer. de Vathaire, F. Schlumberger, M. Delisle, M. J. Francese, C. Challeton, C. de la Genardiére, E. Meunier, F. Parmentier, C. Hill, C. Sancho-Garnier, H. Br J Cancer Research Article We studied 1771 patients treated for a thyroid cancer in two institutions. None of these patients had been treated with external radiotherapy and 1497 had received (131)I. The average (131)I cumulative activity administered was 7.2 GBq, and the estimated average dose was 0.34 Sv to the bone marrow and 0.80 Sv to the whole body. After a mean follow-up of 10 years, no case of leukaemia was observed, compared with 2.5 expected according to the coefficients derived from Japanese atomic bomb survivors (P = 0.1). A total of 80 patients developed a solid second malignant neoplasm (SMN), among whom 13 developed a colorectal cancer. The risk of colorectal cancer was found to be related to the total activity of (131)I administered 5 years or more before its diagnosis (excess relative risk = 0.5 per GBq, P = 0.02). These findings were probably caused by the accumulation of (131)I in the colon lumen. Hence, in the absence of laxative treatment, the dose to the colon as a result of (131)I administered for the treatment of thyroid cancer could be higher than expected from calculation of the International Commission on Radiological Protection (ICRP). When digestive tract cancers were excluded, the overall excess relative risk of second cancer per estimated effective sievert received to the whole body was -0.2 (P = 0.6). IMAGES: Nature Publishing Group|1 1997 /pmc/articles/PMC2063327/ /pubmed/9043033 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
de Vathaire, F.
Schlumberger, M.
Delisle, M. J.
Francese, C.
Challeton, C.
de la Genardiére, E.
Meunier, F.
Parmentier, C.
Hill, C.
Sancho-Garnier, H.
Leukaemias and cancers following iodine-131 administration for thyroid cancer.
title Leukaemias and cancers following iodine-131 administration for thyroid cancer.
title_full Leukaemias and cancers following iodine-131 administration for thyroid cancer.
title_fullStr Leukaemias and cancers following iodine-131 administration for thyroid cancer.
title_full_unstemmed Leukaemias and cancers following iodine-131 administration for thyroid cancer.
title_short Leukaemias and cancers following iodine-131 administration for thyroid cancer.
title_sort leukaemias and cancers following iodine-131 administration for thyroid cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063327/
https://www.ncbi.nlm.nih.gov/pubmed/9043033
work_keys_str_mv AT devathairef leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT schlumbergerm leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT delislemj leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT francesec leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT challetonc leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT delagenardieree leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT meunierf leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT parmentierc leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT hillc leukaemiasandcancersfollowingiodine131administrationforthyroidcancer
AT sanchogarnierh leukaemiasandcancersfollowingiodine131administrationforthyroidcancer